Whether the anti-CD52 monoclonal antibody alemtuzumab can be an effective treatment option for late antibody-mediated rejection (ABMR) is not known. In a single-center pilot study, 12 patients with ABMR were given 30 mg subcutaneous alemtuzumab.Median time from transplantation to biopsy was 22 months 10 of recipients fulfilling criteria histologic diagnosis chronic-active ABMR. The estimated gl...